ClinicalTrials.gg
RecruitingNCT05003310Updated May 22, 2024

ConsideRAte Study - Splenic Stimulation for RA

An interventional study of Active Stimulation and Sham Stimulation in Rheumatoid Arthritis, sponsored by Galvani Bioelectronics. Recruiting at 14 sites in 2 countries. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Galvani Bioelectronics · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
22 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Planned enrollment
19th of 23
28 · median 290
Started
2021
with 1 other
No phase
Only one
of the 23
Registered
16th of 23
by date
Lead sponsor
1 of 23
Galvani Bioelectronics

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 19th largest by planned enrollment, is one of 2 that started in 2021, is the only one with no phase, and was the 16th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 22 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device implantation.

Read the detailed description

Participants with active rheumatoid arthritis (RA) who receive the implantable system will be randomly assigned to receive either active stimulation or sham-stimulation for 12 weeks (Period 1).

Following Period 1, all participants will enter an open label phase (Period 2) during which participants who responded to stimulation will continue on stimulation; whereas participants who received sham stimulation, or were stimulation non-responders, will receive a market-approved RA drug for 12 weeks.

At the end of Period 2, participants who respond to their Period 2 therapy but still exhibit signs and symptoms of RA will enter the Treat-to-target period (Period 3); others will proceed to Period 4 (Long-term Follow-up). During the Treat-to-Target period, participants will be treated with dual therapy (stimulation in combination with the market-approved RA drug) for up to 24 weeks.

Period 4 provides long term safety follow up for all study participants for a period of 5 years. Participants may receive stimulation in combination with other approved and standard of care therapies, subject to a favorable benefit-risk assessment in the judgement of the treating rheumatologist.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Electrical stimulation
  • random allocation
  • inflammation
  • active implantable medical device
  • Laparoscopy
  • antirheumatic agents
  • autonomic nervous system
  • feasibility studies
04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RA of at least six months duration, per 2010 ACR/EULAR criteria
  • Male or female participants, 22-75 years of age
  • Active RA
  • Inadequate Response to at least 2 biologic DMARDs and/or JAK-inhibitors (JAKis) including at least one TNF inhibitor
  • Have an appropriate from previously used biological DMARDs or JAKi
  • Receiving current treatment with standard dose(s) of conventional synthetic DMARD(s) or have documented history of failure due to ineffectiveness or intolerance

Exclusion criteria

Exclusion Criteria:

  • Inability to provide
  • Significant psychiatric disease or substance abuse
  • History of unilateral or bilateral vagotomy
  • Active or latent tuberculosis
  • Known infection with (HIV); current acute or chronic or ; previous hepatitis B
  • Positive SARS COV 2 PCR screening test for COVID-19 infection (at the point of screening for this study)
  • Currently implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)
  • Previous splenectomy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Active Stimulation; Period 1

    Active stimulation for 12 weeks

    Device: Active Stimulation · Drug: Background Treatment

  • Sham comparator
    Sham Stimulation; Period 1

    Sham stimulation for 12 weeks

    Device: Sham Stimulation · Drug: Background Treatment

  • Experimental
    Open label active stimulation, Period 2

    Open label active stimulation for 12 additional weeks

    Device: Active Stimulation · Drug: Background Treatment

  • Other
    Open label RA Drug, Period 2

    Open label drug treatment with baricitinib for 12 weeks

    Drug: Baricitinib · Drug: Background Treatment

  • Experimental
    RA drug combined with active stimulation, Period 3

    Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks

    Device: Active Stimulation · Drug: Baricitinib · Drug: Background Treatment

  • Experimental
    Active stimulation combined with RA drug, Period 3

    Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks

    Device: Active Stimulation · Drug: Baricitinib · Drug: Background Treatment

  • Other
    Long-term Follow-up, Period 4

    Standard of care treatments with or without stimulation

    Device: Active Stimulation · Drug: Background Treatment

Interventions

  • DeviceActive Stimulation

    Stimulation will be turned ON and applied during each day of the period.

  • DeviceSham Stimulation

    Sham stimulation will be provided during the period

  • Baricitinib (2 mg) is administered daily during the period.

  • DrugBackground Treatment

    Stable dose of standard background treatment (e.g., csDMARD therapy)

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events [Safety and Tolerability]

    Adverse Events (AEs) may include clinically significant findings from Laboratory Safety Assessments (clinical chemistry and hematology), vital signs (blood pressure, heart rate, respiratory rate, and body temperature), and 12-Lead EKG

    Time frame: Up through the end of Period 1 (Period 1 is up to 12 weeks duration)

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: During Period 2 (Period 2 is up to 12 weeks in duration beyond Period 1)

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: During Period 3 (Period 3 is up to 24 weeks in duration beyond Period 2)

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: During Period 4 (Period 4 is up to 5 years in duration beyond Period 3)

Secondary outcomes

  1. Change in the 28 Joint Disease Activity Score 28 - C reactive protein (DAS28-CRP)

    Time frame: Baseline to 12 weeks (Period 1)

  2. Change in the level of Lipopolysaccharide (LPS)-inducible release of Tumor Necrosis Factor (TNFα) in whole blood assay

    Time frame: Baseline to 12 weeks (Period 1)

  3. Change in the level of LPS-inducible release of TNFα in whole blood assay

    Time frame: Baseline to 24 weeks (Period 2)

  4. Change in the level of LPS-inducible release of Interleukin 6 (IL-6) in whole blood assay

    Time frame: Baseline to 12 weeks (Period 1)

  5. Change in the level of LPS-inducible release of Interleukin 6 (IL-6) in whole blood assay

    Time frame: Baseline to 24 weeks (Period 2)

  6. Change in the level of LPS-inducible release of IL-8 in whole blood assay

    Time frame: Baseline to 12 weeks (Period 1)

  7. Change in the level of LPS-inducible release of IL-8 in whole blood assay

    Time frame: Baseline to 24 weeks (Period 2)

  8. Change in the level of LPS-inducible release of IL-17 in whole blood assay

    Time frame: Baseline to 12 weeks (Period 1)

  9. Change in the level of LPS-inducible release of IL-17 in whole blood assay

    Time frame: Baseline to 24 weeks (Period 2)

  10. Change in DAS28-CRP

    Time frame: Baseline to 24 weeks (Period 2)

  11. Change in DAS28-CRP

    Time frame: Baseline to 36 weeks (Period 3)

  12. Change in DAS28-CRP

    Time frame: Baseline to 48 weeks (Period 3)

  13. Change in Health Assessment Questionnaire Disability Index (HAQ-DI) score

    Time frame: Baseline to 12 weeks (Period 1)

  14. Change in HAQ-DI score

    Time frame: Baseline to 24 weeks (Period 2)

  15. Change in HAQ-DI score

    Time frame: Baseline to 36 weeks (Period 3)

  16. Change in HAQ-DI score

    Time frame: Baseline to 48 weeks (Period 3)

  17. Change in Short Form 36 (SF-36) physical component score

    Time frame: Baseline to 12 weeks (Period 1)

  18. Change in SF-36 physical component score

    Time frame: Baseline to 24 weeks (Period 2)

  19. Change in SF-36 physical component score

    Time frame: Baseline to 36 weeks (Period 3)

  20. Change in SF-36 physical component score

    Time frame: Baseline to 48 weeks (Period 3)

  21. Change in SF-36 mental component score

    Time frame: Baseline to 12 weeks (Period 1)

  22. Change in SF-36 mental component score

    Time frame: Baseline to 24 weeks (Period 2)

  23. Change in SF-36 mental component score

    Time frame: Baseline to 36 weeks (Period 3)

  24. Change in SF-36 mental component score

    Time frame: Baseline to 48 weeks (Period 3)

  25. Change in SF-36 domain score

    Time frame: Baseline to 12 weeks (Period 1)

  26. Change in SF-36 domain score

    Time frame: Baseline to 24 weeks (Period 2)

  27. Change in SF-36 domain score

    Time frame: Baseline to 36 weeks (Period 3)

  28. Change in SF-36 domain score

    Time frame: Baseline to 48 weeks (Period 3)

  29. To evaluate the usability of the external Galvani System devices and accessories

    Summarize feedback collected on a questionnaire pertaining to the use of the external Galvani System devices

    Time frame: Through 48 weeks

  30. To evaluate the participants' perception of therapy and sensation

    A form is provided to participants at each visit after randomization to describe any sensations that may be associated with the Galvani System

    Time frame: Through 48 weeks

  31. Evaluate device performance as assessed by tabulation of device deficiencies

    Time frame: Through 48 weeks

  32. Change in DAS28-CRP in participants who remain on active stimulation during Period 2

    Time frame: week 12 to week 24

  33. Incidence of participants who remain on active stimulation achieving DAS28-CRP score <2.6 at the end of Period 2

    Time frame: Time Frame: Week 24

  34. Change in DAS28-CRP in participants who are given Drug treatment with baricitinib during Period 2

    Time frame: week 12 to week 24

  35. Incidence of a change in DAS28-CRP greater than 1.2 units in participants who are given Drug treatment with baricitinib during Period 2

    Time frame: week 12 to week 24

  36. Incidence of participants who are given drug treatment with baricitinib achieving DAS28-CRP score <2.6 at the end of Period 2

    Time frame: Week 24

07

Study locations

12 of 14 sites recruiting
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
    Withdrawn

    Not enrolling at this site.

  • Medvin Research - Covina
    Covina, California 91722, United States
    Recruiting
  • Medvin Research - Whittier
    Whittier, California 90602, United States
    Recruiting
    • Study Coordinator · ContactInfo@medvinresearch.com · 562-758-6600
    • Tien-I Karleen Su, MD · Principal investigator
  • The Osteoporosis & Clinical Trials Center
    Hagerstown, Maryland 21740, United States
    Recruiting
  • NYU Langone
    Brooklyn, New York 11201, United States
    Recruiting
    • Galvani Operations Director · Contactclinical@galvani.bio · 877-613-9001
    • David Goddard, MD · Principal investigator
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Cong-Qui Chu, MD · Contact503-494-8637
  • Altoona Center for Clinical Research
    Altoona, Pennsylvania 16635, United States
    Recruiting
    • Study Coordinator · Contact800-924-7790
    • Alan Kivitz, MD · Principal investigator
  • Arthritis & Rheumatology Institute
    Allen, Texas 75013, United States
    Recruiting
    • Study Coordinator · Contact972-798-8553
    • Megha Patel-Banker, MD · Principal investigator
  • St. David's Healthcare
    Austin, Texas 78705, United States
    Recruiting
    • SDH Office of Research; Research Dept · ContactKrishna.Saini@stdavids.com · 512-544-8070
    • Robert J. Koval, MD · Principal investigator
  • Tekton Research
    Austin, Texas 78745, United States
    Recruiting
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
    Withdrawn

    Not enrolling at this site.

  • Southwest Rheumatology Research
    Mesquite, Texas 75150, United States
    Recruiting
    • Study Coordiinator · Contactjointpain@swrr.net · 972-288-2600
    • Atul Singhal, MD · Principal investigator
  • Academic Medical Center (AMC) Dept of Rheumatology & Clinical Immunology
    Amsterdam, Netherlands
    Recruiting
    • Study Coordinator · Contact
    • Sander Tas, MD · Principal investigator
  • Maxima Medical Center, MMC
    Eindhoven, Netherlands
    Recruiting
    • Jasper Broen, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Jul 2027, 69 months after the start.

Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 92. This study's planned 69 months is above that.

Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Aug 12, 2021
StartActual
Oct 19, 2021
Primary completionEst.
Jul 2027
CompletionEst.
Apr 2032
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05003310
Lead sponsor
Galvani Bioelectronics
Collaborators
NAMSA, Q2 Solutions
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Oct 19, 2021
Primary completion
Jul 2027 (estimated)
Completion
Apr 2032 (estimated)
Last update
May 22, 2024

Study contacts

Operations Director
Contact
clinical@galvani.bio
+1 877 613 9001

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion